Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort-Reference-Cited by-同舟云学术

Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort

Published:2024-07 Issue:7 Volume:63 Page:1045-1054
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Meertens Marinda,Giraud Eline L.,van der Kleij Maud B. A.,Westerdijk Kim,Guchelaar Niels A. D.,Bleckman Roos F.,Rieborn Amy,Imholz Alex L. T,Otten Hans-Martin,Vulink Annelie,Los Maartje,Hamberg Paul,van der Graaf Winette T. A.,Gelderblom Hans,Moes Dirk Jan A. R.,Broekman K. Esther,Touw Daan J.,Koolen Stijn L. W.,Mathijssen Ron H. J.,Huitema Alwin D. R.,van Erp Nielka P.,Desar Ingrid M. E.,Steeghs Neeltje^ORCID,

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40262-024-01399-8.pdf

Reference19 articles.

1. Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up(☆). Ann Oncol. 2021;32(11):1348–65.

2. von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, et al. Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(7):815–33.

3. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.

4. European Medicines Agency. Summary of product characteristics Vortrient 200 and 400 mg film-coated tablets. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/votrient. Cited 15 Aug 2023.

5. Westerdijk K, Desar IME, Steeghs N, van der Graaf WTA, van Erp NP, Dutch P, Oncology G. Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br J Clin Pharmacol. 2020;86(2):258–73.